On 24 August 2018, orphan designation (EU/3/18/2067) was granted by the European Commission to Omeros London Limited, United Kingdom, for recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (also known as OMS721) for treatment in haematopoietic stem cell transplantation.
EU/3/18/2067: Public summary of opinion on orphan designation: Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (PDF/127.23 KB)
First published: 19/12/2018
Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2
|Disease / condition||
Treatment in haematopoietic stem cell transplantation
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;